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B caused by deficiency in factor VIII (FVIII) and factor 
IX (FIX), respectively, are most common. The incidence 
of hemophilia A (1 in 5000 males) is approximately six 
times higher than that of hemophilia B (Mannucci and 
Tuddenham 2001). Based on coagulation factor activity 
in a patient’s plasma, hemophilia cases can be classified 
into one of three types: mild (5–30 % activity), moderate 
(1–5 % activity), or severe (<1 % activity) (Graw et al. 
2005). Severe cases show frequent spontaneous bleed-
ing episodes in joints, muscles, and soft tissues, and the 
symptoms may progress to chronic synovitis, debilitating 
arthropathy, and other physical disabilities (Chuah et al. 
2013).
One current hemophilia treatment option involves intra-
venous infusion of recombinant FVIII or FIX concentrate. 
Due to the short half-life of these factors, however, patients 
with severe hemophilia must receive the treatment 2–3 
times per week throughout their lifetimes. Moreover, this 
remedy is costly, and some patients generate a neutralizing 
antibody against the infused factor. Because the clotting 
factor infusion is more a preventive approach for avoiding 
bleeding episodes than a curative one, a more permanent 
approach is needed. Gene therapy can potentially fulfill this 
need, because (1) hemophilia is an inherited monogenic 
disease, (2) its symptoms can be improved with a 1 % 
increase of in vivo coagulation activity, and (3) the patient’s 
phenotype can be improved through a stable supply of ther-
apeutic proteins, such as FVIII and FIX, instead of having 
cells producing the coagulation factors. The previous stud-
ies tested several vector delivery systems targeting vari-
ous cell types to pursue gene therapy options. Out of these 
delivery vector systems, adeno-associated virus (AAV)-
mediated approach attracts attention, which has big poten-
tiality in safety or delivery efficiency aspect. However, 
this approach still has limitations in that the expression of 
Abstract Hemophilia is caused by various mutations 
in blood coagulation factor genes, including factor VIII 
(FVIII) and factor IX (FIX), that encode key proteins in 
the blood clotting pathway. Although the addition of thera-
peutic genes or infusion of clotting factors may be used to 
remedy hemophilia’s symptoms, no permanent cure for the 
disease exists. Moreover, patients often develop neutraliz-
ing antibodies or experience adverse effects that limit the 
therapy’s benefits. However, targeted gene therapy involv-
ing the precise correction of these mutated genes at the 
genome level using programmable nucleases is a promising 
strategy. These nucleases can induce double-strand breaks 
(DSBs) on genomes, and repairs of such induced DSBs by 
the two cellular repair systems enable a targeted gene cor-
rection. Going beyond cultured cell systems, we are now 
entering the age of direct gene correction in vivo using 
various delivery tools. Here, we describe the current status 
of in vivo and ex vivo genome-editing technology related 
to potential hemophilia gene correction and the prominent 
issues surrounding its application in patients with mono-
genic diseases.
Introduction
Hemophilia, an inherited bleeding disorder, can be caused 
by deficiency in various blood coagulation factor pro-
teins. As an X-linked recessive disorder, hemophilia A and 
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therapeutic genes is not permanent, as the viral genome 
containing therapeutic gene is maintained in a form of epi-
some, an unwanted insertional mutation may be induced, 
or unintended side effects (e.g., hepatitis) may result from 
immune responses (High 2011; Chuah et al. 2012).
To overcome these limitations, researchers have investi-
gated the genomic correction of mutated genes via genome-
editing (Cox et al. 2015). Targeted genome-editing can be 
achieved using programmable nucleases, including zinc-
finger nuclease (ZFN), transcription activator-like effec-
tor nuclease (TALEN), and clustered regularly interspaced 
short palindromic repeat (CRISPR)/CRISPR-associated 
protein 9 (Cas9) systems (Kim and Kim 2014) that can 
induce DSBs at specific genomic loci. Depending on the 
cell cycle stage and the presence or the absence of donor 
template, nuclease-induced DSBs are typically repaired by 
one of two major cellular repair systems: error-prone non-
homologous end joining (NHEJ) and error-free homology-
directed repair (HDR). NHEJ is a highly efficient repair 
system which directly ligates two ends, where DSBs is 
created. During the repairing process by this mechanism, 
small insertions and deletions (indels) can be induced in the 
DSB site. On the other hand, HDR is a high-fidelity repair 
system that occurs when exogenous template or sister 
chromatids to homologous sequence is involved. Although 
NHEJ-mediated editing is more efficient than HDR-medi-
ated editing, HDR system may induce largely error-free 
repairs. Thus, it has been widely used to correct the mono-
genetic diseases including hemophilia. However, it has 
been reported that gene correction utilizing NHEJ is also 
possible in the following cases (Anguela et al. 2013; Park 
et al. 2015): when it is difficult to prepare a homologous 
donor (e.g., large chromosomal inversion), and in the case 
of excluding homologous arm hierarchy to deliver a long 
therapeutic gene using AAV vector which has relatively 
high restraints on cargo sizes.
Various genomic rearrangements (indels, targeted large 
deletions, inversions, duplications, translocations, and 
gene knock-ins/-outs) may occur during the repair of one 
or more induced DSBs. In fact, the gene targeting strategy 
has long been used, but with the dazzling advance of pro-
grammable nucleases, the efficiency of targeting has been 
enhanced dramatically.
These technologies are being adopted actively for 
in vivo or ex vivo studies correcting mutated genes that 
cause inherited monogenic diseases, such as hemophilia. 
Especially, the development of a delivery system for 
in vivo genome-editing which does not require ex vivo 
manipulation step is actively in progress. According to Li 
et al. (2011), nuclease-mediated in vivo editing utilizing 
AAV vector delivery system can be made in a tissue spe-
cific manner. Up to now, AAV vector is being considered 
as a more promising delivery tool for in vivo editing. Thus, 
a smaller version Cas9 that can overcome packaging size 
limitation of AAV vector has been developed (Ran et al. 
2015), and its safety was verified through the recently 
reported AAV-mediated clinical approach (Nathwani et al. 
2014). Although safety aspects or high immunogenic-
ity aspects should be improved in the future, lentiviral 
(Sánchez-Rivera et al. 2014) and adenoviral vectors (Cheng 
et al. 2014) can also be considered as delivery systems with 
in vivo editing potentiality. In addition, although cationic 
lipid-mediated delivery strategy that could deliver a nucle-
ase in a protein form (Zuris et al. 2015) for in vivo editing 
was reported, further studies should identify whether the 
donor DNA delivery capacity and the target cell (or tissue) 
specificity are covered. Here, we discuss the current status 
of nuclease-mediated genome-editing technology related 
to hemophilia treatment and relevant issues involving the 
application to humans.
In vivo gene correction
The ideal method for curing hemophilia may be the correc-
tion or replacement of mutated coagulation factor genes at 
the genomic level. To this end, researchers are actively con-
ducting in vivo correction experiments combining the con-
cept of nuclease and AAV-mediated gene therapy. Because 
this strategy does not rely on in vitro cell manipulation, 
required in ex vivo systems, it is potentially more advanta-
geous than ex vivo approaches.
Li et al. (2011) constructed two hepatotropic AAVs 
encoding a ZFN and corrective FIX cDNA flanked by 
homology arms and observed that HDR-mediated in vivo 
correction using systemic co-delivery of two AAV vec-
tors was possible in humanized neonatal hemophilic mice. 
Their study is highly meaningful, because it was the first 
successful nuclease–mediated in vivo genome-editing 
attempt and showed that nuclease–mediated DSBs can be 
induced in vivo at a high rate (34–47 %). Although AAV 
was injected intraperitoneally to 2-day-old mice and HDR-
mediated targeting efficiency in their liver tissue was only 
1–3 %, their activated partial thromboplastin time (aPTT) 
was shortened significantly suggesting that nearly complete 
phenotypic correction could be achieved. Subsequent par-
tial hepatectomy experiments showed that therapeutic FIX 
was stably expressed for up to 30 weeks, indicating that 
genomic modification can overcome the limitations of con-
ventional gene therapies and is applicable in infants with 
growing liver tissues.
Anguela et al. (2013) demonstrated that the above 
method was also effective in adult mice. They injected two 
versions of AAV (AAV-ZFN and AAV-donor) intravenously 
into 8-week-old humanized mice and confirmed that circu-
lating FIX was consistently restored to 23 % of the normal 
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level for 60 weeks. Interestingly, they achieved radical 
reduction of off-target frequency using obligate heterodi-
meric ZFN. They also found that both HDR- and NHEJ-
mediated integration could be induced effectively, suggest-
ing that knock-ins can be induced using NHEJ in quiescent 
liver tissue or non-replicating cells. Recently, the same 
research group reported successful correction of FVIII and 
FIX genes through NHEJ- or HDR-dependent mechanisms, 
respectively, in endogenous mouse albumin (mAlb) loci 
(Sharma et al. 2015). An aPTT assay of HDR-dependent, 
FIX-corrected mice revealed a remarkable functional res-
cue with improved clot forming ability close to the normal 
level. As the Alb locus can be utilized as a safe harbor, it 
is also highly adaptable for correcting other monogenetic 
diseases. When an NHEJ-dependent strategy is used in 
AAV-mediated in vivo correction research, however, AAV-
derived inverted terminal repeats integrate together and thus 
necessitate further determination of unexpected negative 
effects caused by the repeating sequences. Moreover, non-
integrated AAV genome can be detected several months 
after the injection and cause negative effects, such as off-
target mutations and cytotoxicity resulting from the persis-
tent expression of ZFN. The utility of the mAlb locus for 
gene targeting was previously highlighted in another study 
(Barzel et al. 2015) that used an AAV-FIX donor without 
a nuclease and found that HDR-mediated integration was 
possible upstream of the stop codon locus of the Alb gene. 
Correction took place in 0.5 % of tested hepatocytes, and 
FIX expression was restored to approximately 7–20 % of 
the normal level, although additional testing in large ani-
mal models is necessary to assess the method’s applicabil-
ity in humans. Using a non-nuclease, AAV-FIX donor may 
be significant in terms of safety, because the exclusion of 
a nuclease hypothetically limits occurrence of problematic 
off-target mutations. If HDR efficiency could be enhanced 
further, the method may be applicable in humans.
According to another recent report, distinguished from 
the strategies targeting a safe harbor locus as described 
above, in vivo gene correction was made directly for dis-
ease-causing point mutation in the endogenous FIX locus 
(Guan et al. 2016). They delivered Cas9- and the donor-
encoded DNA as a naked DNA vector to liver tissue by 
hydrodynamic injection and attained single-stranded DNA 
oligonucleotides (ssODNs)- and plasmid donor-mediated 
HDR efficiency of 0.56 and 1.55 %, respectively. Inter-
estingly, a genome-editing efficiency of 0.56 % restored 
hemostasis in established FIXY381D mice. Because such 
naked DNA is non-immunogenic in vivo, this is consid-
ered an in vivo genome-editing strategy with a potential, 
although this strategy seems difficult to be actually applied 
to human subjects. In this way, bringing conventional gene 
therapy tools to the genome-editing field makes editing 
in vivo systems on a chromosome level possible. In the case 
of in vivo genome-editing, however, it is currently not pos-
sible to sort out cells with an unwanted mutation or conduct 
genotyping among edited cells. Therefore, a prior thorough 
examination of the desired nuclease system’s safety and 
accuracy must be performed. Moreover, additional efforts 
should be made for patients with antibodies against AAV.
Ex vivo gene correction
Ex vivo gene correction is another strategy to cure hemo-
philia. Because transplantation of autologous cells with 
restored genes can avoid immune rejection and allow gen-
otypic and phenotypic examination before transplanting 
the cells, patient-specific induced pluripotent stem cells 
(iPSCs), in particular, are an important resource in regen-
erative therapies. They have unlimited self-renewal abil-
ity, can be grown as single cell-derived clones, and have 
the ability to be differentiated into different types of cells 
composing the human body. However, patient-specific 
iPSC-based therapies must avoid possible residual pluripo-
tent stem cells or unwanted other type of cells remaining 
in culture, and must detect and eliminate random and rela-
tively rare genetic mutations that could be acquired during 
multiple cell divisions to prevent possible tumor formation. 
Despite the tumorigenicity hurdle, iPSC-based therapeu-
tic approaches have shown their potential for regenerative 
medicine in animal models and a clinical trial for age-
related macular degeneration is undergoing (Kimbrel 
and Lanza 2015; Trounson and DeWitt 2016). Therefore, 
patient-specific iPSCs have potentially significant utility in 
ex vivo gene correction.
In early studies, the possibility of nuclease-mediated 
gene correction was assessed using healthy cells ex vivo 
because of difficulty in obtaining cells from patients. Lee 
et al. (2012) prepared a ZFN targeting the intron 1 homol-
ogy region of FVIII and attempted to build an intron 1 
inversion model through transfecting HEK-293 cells with 
normal FVIII genome structure. Although inversion effi-
ciency was low, and indels related to NHEJ-mediated repair 
were observed, the outcome suggested the possibility that 
genomic inversion can be corrected close to its original 
state by this nuclease. Such modeling research was also 
adopted in attempts to use TALEN in normal iPSCs (Park 
et al. 2014). With the use of TALEN, the inversion effi-
ciency increased to over 1 %, albeit still low. However, the 
hemophilia phenotype, which could not be shown in HEK-
293 cells due to the presence of three X chromosomes, was 
reproduced. Furthermore, the study showed that therapeutic 
FVIII expression can be rescued at the chromosomal level 
by reverting an intron 1 inverted segment to its normal orien-
tation using the same nuclease. This finding led to research 
with patient-derived iPSCs, which determined that large 
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inversion types (e.g., intron 1 and 22 inversions) of FVIII 
can be reverted using CRISPR/Cas9 (Park et al. 2015). 
Analysis of off-target mutations through deep and whole-
genome sequencing in corrected clones revealed no sig-
nificant mutations. Although FVIII deficiency in mice can 
be rescued to some degree by transplantation of corrected 
iPSC-derived endothelial cells, further research is necessary 
to address the low corrective effect of the cells, including 
their efficient differentiation to liver sinusoidal endothe-
lial cells (LSECs, known as major FVIII producing cells), 
optimization of the transplantation site, and the enhanced 
survival of transplanted cells. The inverted genome struc-
ture can be also successfully restored to its normal direction 
through transfection of the Cas9/sgRNA ribonucleoprotein 
complex. Because the complex has a short half-life, this 
approach minimizes unwanted off-target effects and can 
potentially prevent random insertional mutations of vector 
DNA, making it a promising strategy for improving ex vivo 
therapy of monogenic diseases.
A recent study of TALEN-mediated knock-in intro-
duced another strategy for correcting intron 22 inversion in 
endogenous loci (Wu et al. 2016). Using intron 22 inverted 
patient-iPSCs, they successfully induced HDR-medi-
ated targeted integration by inserting normal exon 23–26 
sequences in frame after an inverted exon 22 locus. Showing 
a high targeting efficiency (52.9–62.5 %) through antibiotic-
based selection, they demonstrated the potential use of this 
strategy for correcting inversion, deletion, and point muta-
tion genotypes. For example, correcting a point mutation 
via knock-in with easily preparable ssODNs donors can be 
used instead of plasmid donors. Low targeting efficiency is 
expected, because antibiotic-based selection cannot be used, 
but PCR-based single colony analysis could be performed to 
obtain scarless clones. Their study confirmed that functional 
FVIII proteins are secreted by endothelial and mesenchymal 
stem cells differentiated from corrected iPSCs. However, 
additional rescue experiments with animal models should be 
pursued to determine its therapeutic potential.
Knock-in of functional FVIII in a safe harbor locus is 
another important option for ex vivo gene correction and 
is useful because of its applicability to monogenic diseases 
other than hemophilia. Particularly for hemophilia A, such 
a knock-in strategy can help identify corrective pheno-
types by ex vivo therapy in cell types other than LSECs, 
which do not easily differentiate. Using iPSC models of 
severe hemophilia, Pang et al. (2016) performed a knock-
in of CMV promoter-derived BDD FVIII cDNA using 
transcription activator-like effector nickase targeting an 
rDNA locus. Although further functional rescue studies are 
required, this study revealed the potential of rDNA locus 
as a safe harbor genomic locus. Moreover, Sivalingam 
et al. (2016) knocked-in a corrective FVIII gene in adeno-
associated site 1 locus using ZFN fused with an enhanced 
FokI-Sharkey domain, and reported the secretion of stable 
FVIII protein in human umbilical cord-lining epithelial 
cells and bone marrow-derived stromal cells. Some of the 
above-mentioned studies detected off-target events that 
could be resolved in the future, and the approaches’ poten-
tial efficacy in animal models should be tested extensively. 
Nevertheless, ex vivo gene correction, which can isolate 
clones without off-target mutations via genome-wide anal-
ysis, provides a promising avenue for clinical studies.
Conclusion
The application of nucleases technology to precisely induce 
DSBs at a desired genomic locus enables effective targeted 
gene editing that could be used to treat genetic diseases. For 
example, the Sangamo Biosciences research group is prepar-
ing a clinical trial on ZFN-mediated in vivo genome-editing 
in severe-case hemophilia B patients (https://clinicaltrials.
gov/ct2/show/NCT02695160), from which we expect to see 
a significant therapeutic effect. However, the technique’s 
editing efficiency, frequency of unexpected mutations, 
and adverse effects remain unknown, and the safety of this 
approach must be resolved prior to its regular application 
in human patients. Because phenotypic correction of hemo-
philia can be achieved with a low corrective efficiency, a 
strategy for minimizing unexpected mutations should also be 
explored. Thus, modified Cas9 with highly enhanced target 
specificity could be very useful in clinical genome-editing 
(Slaymaker et al. 2016; Kleinstiver et al. 2016). The recently 
reported cytidine deaminase-fused Cas9 version that edits 
specific base without DSBs can be considered as another 
option to correct specific point mutations, potential causes 
of hemophilia (Komor et al. 2016). Also, the use of mRNA 
or protein for the nucleases could effectively reduce off-
target activities and limit cell-mediated immune responses 
(Kim et al. 2014; Hendel et al. 2015), although these strate-
gies for in vivo delivery need further improvement. In addi-
tion, unbiased genome-wide analysis should be utilized to 
detect off-target mutations (Bolukbasi et al. 2015), especially 
methods for identifying low-frequency off-target mutations. 
Finally, keeping pace with the progression of genome-edit-
ing technology, understanding/perception of the society and 
institutional procedures needs to be improved for the further 
development of the field. Unless there are any ethical issues 
involved, this technology is considered to be a promising 
option that gives opportunities for better life to hemophilia 
patients as well as other genetic disease patients.
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